Table 3 Conventionally fractionated stereotactic radiation therapy in recurrent  patients with glioblastoma
From: Current status and recent advances in reirradiation of glioblastoma
Author | Pts | Interval between RT courses | RT modality | Median dose/fractions | Imaging for planning | Median target volume (ml) | CTV/PTV margins (mm) | Systemic therapy | Median PFS (months) | Median OS (months) | EQD2 (Gy) | Cumulative EQD2 (Gy) | RN (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Combs et al., 2005 [74] | 59 | 10 | LINAC | 36 Gy/18 fr | T1-w ce MRI | 49.3 (2.5–636) | 5–10 mm | TMZ, Carmustine, PCV, 36 | 5 (1–21) | 8 23% at 1 year | 36 | 96 | 0.6 |
Sholtyssek et al., 2013 [75] | 53 | 13.4 | LINAC | 36 Gy/18 fr* | T1-w ce MRI | 110.4. (1.8– 378) | CTV, 5 mm; PTV, 3–5 mm | TMZ,12; Carbo/etoposide, 24 | 4.3 33% at 6 m | 7.7 24% at 1 year | 36 | 96 | 0 |
Flieger et al., 2014 [76] | 49 | NR | LINAC | 36 Gy/18 fr* | T1-w ce MRI | 34.9 (1.95–157.9) | 5–10 mm | CHT, 38; BEV,18 | 4.9 | 7.8 | 36 | 96 | 0 |
Wick et al., 2014 [77] | 91 | 21 | LINAC | 36 Gy/18 fr | T1-w ce MRI | size > 2.5 cm in 35 pts | 10 mm | SRT + APG101, 58 SRT, 21 | 2.5. 4.5(+ APG101) | SRT, 11.5; SRT + APG101, 11.5 | 36 | 96 | 1.2 |
Schnell et al., 2017 [78] | 85 | 18.5 | LINAC | 36 Gy/18 fr | T1-w ce MRI | 128 | 5–10 mm | Concomitant BEV, 33; Concomitant/ manteinance BEV, 25; BEV + IRI, 27 | NR | concomitant BEV, 8; concomitant/ manteinance BEV, 13.1; BEV + IRI, 6.6 | 36 | 96 | 0 |
Shen et al., 2018 [79] | 63 | 27.6 | LINAC | 41.4 Gy/23 fr | T1-w ce, DCE, DSC MRI | 202 (20–901) | 5–10 mm | TMZ, 35; BEV, 5; TMZ/BEV, 6 | NR | 6.7 | 41.4 | 101.4 | 3.4 |
Fleischmann et al., 2019 [30] | 124 | 18 | LINAC | 36 Gy/18 fr* | T1-w ce MRI | 118.1 (22.6–385.5) | CTV, 5 mm PTV, 3 mm | BEV, 95 | 5 | 9 | 36–48.4 | 96–108.4 | 6.9 |